Capricor Therapeutics Inc. (NASDAQ:CAPR) dropped fresh data from its ongoing HOPE-3 open-label extension study on Monday. The biotech is testing its lead asset, Deramiocel, which is aimed at treating upper limb impairment in patients with Duchenne muscular dystrophy (DMD).

Deramiocel is currently under FDA review, with a decision date of November 22. That's the number that matters here, and it's the reason every new data point gets scrutinized like a job interview.

Rewind to July: the FDA's advisory panel voted 9-3 that the company failed to provide sufficient evidence supporting Deramiocel's effectiveness. That echoed FDA staff concerns over post hoc changes to key analyses after the late-stage trial concluded. Not exactly a ringing endorsement.

Then came Monday's FDA briefing document, in which staff noted that the submitted data from Study HOPE-3, considered together with results from Study HOPE-2, do not provide substantial evidence of effectiveness for Deramiocel in DMD. So the agency's position hasn't exactly softened.

Reduced Rate Of Decline

The trial results themselves highlight a significant reduction in the rate of disease progression. Patients in the delayed-start placebo group experienced a 2.05-point decline in their PUL 2.0 total score during their first year.

But after transitioning to Deramiocel in the second year, that decline slowed to just 0.49 points. That's a 76% reduction in the rate of functional loss. In plain English: the disease kept moving, just a lot more slowly.

Meanwhile, the early-start cohort receiving Deramiocel continuously showed consistent stabilization, declining by 0.95 points in the first year and 0.89 points in the second year.

The Performance of Upper Limb (PUL 2.0) is a specialized, 22-item clinical assessment tool designed to measure arm and hand function in DMD patients across both ambulant (walking) and non-ambulant (wheelchair-using) stages.

Outperforming Natural History

After 24 months, both study groups demonstrated favorable outcomes compared to natural history predictions.

The early-start arm observed a 3.42-point decline versus a predicted 5.88-point drop, underscoring the therapy's ability to preserve upper limb function in patients over an extended period.

The delayed-start arm also outperformed natural history, recording a 3.76-point drop compared to a predicted 5.35-point decline.

CAPR Price Action: Capricor Therapeutics shares were down 9.39% at $8.11 at the time of publication on Monday, according to market data.